## Ian J Welsby

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3731259/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Management of Perioperative Iron Deficiency in Cardiac Surgery: A Modified RAND Delphi Study. Annals of Thoracic Surgery, 2022, 113, 316-323.	0.7	12
2	Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. Journal of Thrombosis and Thrombolysis, 2022, 53, 167-175.	1.0	20
3	Prothrombin Complex Concentrate vs Plasma for Post–Cardiopulmonary Bypass Coagulopathy and Bleeding. JAMA Surgery, 2022, 157, 757.	2.2	26
4	Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 3299-3302.	0.6	6
5	Modulation of red blood cell oxygen affinity with a novel allosteric modifier of hemoglobin is additive to the Bohr effect. Blood Cells, Molecules, and Diseases, 2021, 87, 102520.	0.6	4
6	Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparinâ€induced thrombocytopenia. Vox Sanguinis, 2021, 116, 217-224.	0.7	10
7	Conventional Ultrafiltration During Elective Cardiac Surgery and Postoperative Acute Kidney Injury. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1310-1318.	0.6	13
8	Heated Humidified Breathing Circuit Rewarming in Hypothermic Patients Post-Cardiopulmonary Bypass—Pilot Study. Journal of Cardiothoracic and Vascular Anesthesia, 2021, , .	0.6	0
9	Blood product transfusion and lung transplant outcomes: A systematic review. Clinical Transplantation, 2021, 35, e14404.	0.8	5
10	Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis. Blood Coagulation and Fibrinolysis, 2021, 32, 87-102.	0.5	5
11	Optimizing management of sickle cell disease in patients undergoing surgery. Hematology American Society of Hematology Education Program, 2021, 2021, 405-410.	0.9	4
12	Intrapulmonary Activated Factor VII for Hemoptysis Complicating Pulmonary Thromboendarterectomy. Annals of Thoracic Surgery, 2020, 109, e243-e245.	0.7	2
13	ABO Blood Group and Transfusions In the Intraoperative and Postoperative Period After LVAD Implantation. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 906-911.	0.6	3
14	Prothrombin Complex Concentrate Use in Durable and Short-Term Left Ventricular Assist Device Implantation. ASAIO Journal, 2020, 66, e8-e10.	0.9	3
15	When Therapy Is Confounded With Approach: Retrospective Studies of Transfusion-Related Outcomes After Lung Transplantation. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 3021-3023.	0.6	0
16	COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thrombosis Research, 2020, 196, 483-485.	0.8	31
17	Multicenter Evaluation of the Quantra QPlus System in Adult Patients Undergoing Major Surgical Procedures. Anesthesia and Analgesia, 2020, 130, 899-909.	1.1	42
18	Rejuvenation solution as an adjunct cold storage solution maintains physiological haemoglobin oxygen affinity during earlyâ€storage period of red blood cells. Vox Sanguinis, 2020, 115, 388-394.	0.7	2

#	Article	IF	CITATIONS
19	Anticoagulation Strategies in the Perioperative Period for Lung Transplant. Annals of Thoracic Surgery, 2020, 110, e23-e25.	0.7	7
20	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood, 2020, 135, 755-765.	0.6	61
21	Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease. Blood Transfusion, 2020, 18, 200-207.	0.3	4
22	The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation. Blood Transfusion, 2020, 18, 454-464.	0.3	6
23	COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy. Blood, 2020, 136, 23-24.	0.6	Ο
24	Metabolic impact of red blood cell exchange with rejuvenated red blood cells in sickle cell patients. Transfusion, 2019, 59, 3102-3112.	0.8	23
25	Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange. Transfusion, 2019, 59, 2622-2628.	0.8	2
26	Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 2887-2899.	0.6	79
27	Threeâ€factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sanguinis, 2019, 114, 374-385.	0.7	16
28	Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesthesia and Analgesia, 2019, 129, 1209-1221.	1.1	115
29	Protocolized hemostatic factor use in major thoracic aortic surgery. Journal of Cardiovascular Surgery, 2019, 60, 633-636.	0.3	4
30	Metabolomics evaluation of earlyâ€storage red blood cell rejuvenation at 4°C and 37°C. Transfusion, 2018, 58, 1980-1991.	0.8	12
31	Estimation of Achievable Oxygen Consumption Following Transfusion With Rejuvenated Red Blood Cells. Seminars in Thoracic and Cardiovascular Surgery, 2018, 30, 134-141.	0.4	4
32	Epsilon Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Hip and Total Knee Arthroplasty. Journal of Arthroplasty, 2018, 33, 55-60.	1.5	16
33	Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 558-564.	0.6	7
34	Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism. Transfusion, 2018, 58, 2797-2806.	0.8	27
35	Cangrelor use prior to left ventricular assist device surgery: a case series. Journal of Thrombosis and Thrombolysis, 2018, 46, 131-133.	1.0	8
36	Should modulation of p50 be a therapeutic target in the critically ill?. Expert Review of Hematology, 2017, 10, 449-458.	1.0	26

#	Article	IF	CITATIONS
37	Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit. Transfusion Medicine Reviews, 2017, 31, 258-263.	0.9	5
38	Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients. Journal of Thrombosis and Thrombolysis, 2017, 43, 194-202.	1.0	6
39	Point-of-care washing of allogeneic red blood cells for the prevention of transfusion-related respiratory complications (WAR-PRC): a protocol for a multicenter randomised clinical trial in patients undergoing cardiac surgery. BMJ Open, 2017, 7, e016398.	0.8	14
40	Abstract 21142: Ultrafiltration on CPB Predicts AKI and Transfusion. Circulation, 2017, 136, .	1.6	0
41	Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. Anesthesia and Analgesia, 2016, 122, 1287-1300.	1.1	84
42	Does moderate hypothermia really carry less bleeding risk than deep hypothermia for circulatory arrest? A propensity-matched comparison in hemiarch replacement. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1559-1569.e2.	0.4	41
43	Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. Canadian Journal of Anaesthesia, 2016, 63, 1223-1232.	0.7	18
44	New reversal agent for factor Xa inhibitors shows promise. Evidence-Based Medicine, 2016, 21, 96-96.	0.6	2
45	3-Factor Prothrombin Complex Concentrates in Infants With Refractory Bleeding After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 1627-1631.	0.6	18
46	Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Review of Hematology, 2016, 9, 115-122.	1.0	51
47	Using Zero-Balance Ultrafiltration With Dialysate as a Replacement Solution for Toxin and Eptifibatide Removal on a Dialysis-Dependent Patient During Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 162-168.	0.6	1
48	Prolonged postoperative respiratory support after proximal thoracic aortic surgery: Is deep hypothermic circulatory arrest a risk factor?. Journal of Critical Care, 2016, 31, 125-129.	1.0	17
49	Use of human fibrinogen concentrate during proximal aortic reconstruction with deep hypothermic circulatory arrest. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 376-382.	0.4	15
50	Three Factor Prothrombin Complex Concentrates in Cardiac Surgery: A Novel Algorithmic Approach to Perioperative Bleeding. Blood, 2016, 128, 5035-5035.	0.6	2
51	Factor Concentrates for Perioperative Bleeding. Anesthesia and Analgesia, 2015, 121, 4-5.	1.1	Ο
52	Improved Early Survival With a Nonsternotomy Approach for Continuous-Flow Left Ventricular Assist Device Replacement. Annals of Thoracic Surgery, 2015, 99, 561-566.	0.7	21
53	Hyperbaric Oxygen Therapy for Treatment of Neurologic Sequela After Atrioesophageal Fistula. Annals of Thoracic Surgery, 2015, 99, 681-682.	0.7	7
54	ls It Time for Individualized Thromboprophylaxis Regimens in the ICU?*. Critical Care Medicine, 2015, 43, 500-501.	0.4	17

#	Article	IF	CITATIONS
55	Invited Commentary. Annals of Thoracic Surgery, 2015, 99, 768-769.	0.7	О
56	Prolonged pulmonary support after cardiac surgery: incidence, risk factors and outcomes: a retrospective cohort study. Journal of Critical Care, 2015, 30, 940-944.	1.0	26
57	Perioperative Removal of Autologous Platelets. Annals of Thoracic Surgery, 2015, 100, 1970.	0.7	1
58	Split Blood Products. , 2015, , 151-175.		1
59	Prothrombin Complex Concentrates and Cardiac Surgery. Blood, 2015, 126, 4712-4712.	0.6	1
60	Reduced use of allogeneic platelets through highâ€yield perioperative autologous plateletpheresis and reinfusion. Transfusion, 2014, 54, 1348-1357.	0.8	2
61	Case 13—2014. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 1667-1676.	0.6	30
62	Techniques and applications of perioperative therapeutic plasma exchange. Current Opinion in Anaesthesiology, 2014, 27, 57-64.	0.9	18
63	ABO blood group influences transfusion and survival after cardiac surgery. Journal of Thrombosis and Thrombolysis, 2014, 38, 402-408.	1.0	18
64	Arterial Hyperoxia During Cardiopulmonary Bypass and Postoperative Cognitive Dysfunction. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 462-466.	0.6	30
65	Is ABO blood group truly a risk factor for thrombosis and adverse outcomes?. World Journal of Cardiology, 2014, 6, 985.	0.5	35
66	High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood, 2013, 121, 2828-2835.	0.6	50
67	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery. JAMA - Journal of the American Medical Association, 2012, 307, 265-74.	3.8	386
68	The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2. Thrombosis Research, 2012, 129, 793-796.	0.8	12
69	Invited Commentary. Annals of Thoracic Surgery, 2012, 93, 883.	0.7	0
70	Intraoperative Use of Low-Dose Recombinant Activated Factor VII During Thoracic Aortic Operations. Annals of Thoracic Surgery, 2012, 93, 1921-1929.	0.7	54
71	High Incidence of Antibodies to Protamine and Protamine/Heparin Complexes in Patients Undergoing Cardiopulmonary Bypass. Blood, 2012, 120, 3344-3344.	0.6	0
72	An Unusual Cause of Massive Gastrointestinal Bleeding After Transesophageal Echocardiography. Journal of Cardiothoracic and Vascular Anesthesia, 2011, 25, 678-679.	0.6	1

#	Article	IF	CITATIONS
73	Alternate analysis strategies for retrospective assessment of outcomes with a male donor–only plasma policy. Transfusion, 2011, 51, 444-445.	0.8	1
74	Predictors of massive transfusion with thoracic aortic procedures involving deep hypothermic circulatory arrest. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 1283-1288.	0.4	46
75	Perioperative Management of Patients on Clopidogrel (Plavix) Undergoing Major Lung Resection. Annals of Thoracic Surgery, 2011, 92, 1971-1976.	0.7	34
76	HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery. Blood, 2011, 118, 1159-1159.	0.6	0
77	Plasmapheresis and Heparin Reexposure as a Management Strategy for Cardiac Surgical Patients with Heparin-Induced Thrombocytopenia. Anesthesia and Analgesia, 2010, 110, 30-35.	1.1	103
78	Heparin modifies the immunogenicity of positively charged proteins. Blood, 2010, 116, 6046-6053.	0.6	49
79	Glycosylated hemoglobin levels and outcome in non-diabetic cardiac surgery patients. Canadian Journal of Anaesthesia, 2010, 57, 565-572.	0.7	61
80	The relationship of plasma transfusion from female and male donors with outcome after cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 1353-1360.	0.4	33
81	Invited Commentary. Annals of Thoracic Surgery, 2010, 90, 115-116.	0.7	0
82	A clinical prediction tool to estimate the number of units of red blood cells needed in primary elective coronary artery bypass surgery. Transfusion, 2010, 50, 2337-2343.	0.8	14
83	Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion, 2010, 50, 2311-2317.	0.8	29
84	Pathophysiology of Bleeding and Clotting in the Cardiac Surgery Patient. Circulation, 2010, 122, 2068-2077.	1.6	63
85	Many, but not all, outcome studies support exclusion of female plasma from the blood supply. Expert Review of Hematology, 2010, 3, 551-558.	1.0	7
86	Cardiac Angiosarcoma Presenting With Right Coronary Artery Pseudoaneurysm. Journal of Cardiothoracic and Vascular Anesthesia, 2010, 24, 633-635.	0.6	6
87	Association of the 98T ELAM-1 Polymorphism With Increased Bleeding After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2010, 24, 427-433.	0.6	14
88	Heparin Modifies the Immunogenicity of Positively-Charged Proteins Blood, 2010, 116, 1435-1435.	0.6	1
89	The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting. New England Journal of Medicine, 2008, 358, 784-793.	13.9	197
90	Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation. Interactive Cardiovascular and Thoracic Surgery, 2008, 8, 45-48.	0.5	5

#	Article	IF	CITATIONS
91	Influence of Sample Collection and Storage on the Detection of Platelet Factor 4–Heparin Antibodies. American Journal of Clinical Pathology, 2007, 128, 150-155.	0.4	7
92	ABO blood group and bleeding after coronary artery bypass graft surgery. Blood Coagulation and Fibrinolysis, 2007, 18, 781-785.	0.5	29
93	Effect of Combined Anticoagulation Using Heparin and Bivalirudin on the Hemostatic and Inflammatory Responses to Cardiopulmonary Bypass in the Rat. Anesthesiology, 2007, 106, 295-301.	1.3	20
94	Heparin-Induced Thrombocytopenia in Left Ventricular Assist Device Bridge-to-Transplant Patients. Annals of Thoracic Surgery, 2007, 84, 841-846.	0.7	39
95	Invited commentary. Annals of Thoracic Surgery, 2007, 84, 168-169.	0.7	3
96	†Just Say No': A preliminary evaluation of a three-stage model of integrated treatment for substance use problems in conditions of medium security. Journal of Forensic Psychiatry and Psychology, 2007, 18, 141-159.	0.6	30
97	The Kaolin-Activated Thrombelastograph® Predicts Bleeding After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2006, 20, 531-535.	0.6	86
98	Genetics of Coagulation: Considerations for Cardiac Surgery. Seminars in Cardiothoracic and Vascular Anesthesia, 2006, 10, 297-313.	0.4	5
99	Protamine Contributes to Myocardial Ischemia. Anesthesiology, 2005, 103, 669-670.	1.3	2
100	Hemodynamic Changes after Protamine Administration. Anesthesiology, 2005, 102, 308-314.	1.3	75
101	Efficacy and Safety of Heparinase IÂ versus Protamine in Patients Undergoing Coronary Artery Bypass Grafting with and without Cardiopulmonary BypassÂ. Anesthesiology, 2005, 103, 229-240.	1.3	58
102	Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2005, 130, 1567-1572.	0.4	76
103	Central venous access. Foundation Years, 2005, 1, 35-37.	0.0	0
104	Infectious Complications After Cardiac Surgery: Lack of Association With Fresh Frozen Plasma or Platelet Transfusions. Journal of Cardiothoracic and Vascular Anesthesia, 2005, 19, 430-434.	0.6	43
105	Changing systems for measuring activated clotting times: Impact on the clinical practice of heparin anticoagulation during cardiac surgery. Clinica Chimica Acta, 2005, 356, 218-224.	0.5	7
106	Monitoring Direct Thrombin Inhibitors: Time for Standardization. Anesthesiology, 2004, 101, 1048-1049.	1.3	6
107	Systemic air embolism during off-pump coronary artery bypass surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2003, 17, 403-404.	0.6	2
108	The Bispectral Index in the Diagnosis of Perioperative Stroke: A Case Report and Discussion. Anesthesia and Analgesia, 2003, 96, 435-437.	1.1	15

#	Article	IF	CITATIONS
109	Implementing a New Method for Activated Clotting Time:. Point of Care, 2003, 2, 125-128.	0.5	4
110	The Association of Complication Type with Mortality and Prolonged Stay After Cardiac Surgery with Cardiopulmonary Bypass. Anesthesia and Analgesia, 2002, 94, 1072-1078.	1.1	90
111	Pro: Vasopressin is the vasoconstrictor of choice after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2002, 16, 773-775.	0.6	8
112	Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. Journal of Clinical Monitoring and Computing, 2002, 17, 287-292.	0.7	34
113	Gut perfusion during cardiac surgery. Current Opinion in Anaesthesiology, 1997, 10, 34-39.	0.9	3
114	5 Plasma volume support in cardiac surgery. Bailliere's Clinical Anaesthesiology, 1997, 11, 105-125.	0.2	2